Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Fluorouracil better than imiquimod in short-term prevention of subsequent actinic keratoses

04 Apr 2018

A recent study has shown that 5-fluorouracil is significantly more effective than imiquimod in the short-term prevention of subsequent actinic keratoses (AKs).

Treatment with 5-fluorouracil successfully decreased the incidence of subsequent AKs (cumulative risk difference, –4.54 percent; 95 percent CI, –7.91 to –1.17 percent) in the short term. However, no statistically significant evidence was found with regard to a long-term reduced risk (cumulative risk difference, –1.43 percent; –3.43 to 0.05 percent) compared with that with imiquimod.

This community-based cohort study identified adult health plan members who had an AK diagnosed in 2007 and who subsequently filled a prescription for 5-fluorouracil or imiquimod (n=5,700). The investigators followed participants for subsequent AKs identified by the International Classification of Diseases codes and estimated the short- (2 years) and long-term (5 years) differences in cumulative risk while controlling for potential confounding by pretreatment variables.

“This is a retrospective study with limited ascertainment of all relevant potential confounding variables,” the investigators said.

In an earlier study, Tanghetti and Werschler found that 5-fluorouracil cream twice daily for 2–4 weeks was more effective than imiquimod cream twice weekly for 16 weeks in exposing what were presumed to be subclinical AKs, reducing the final AK count, achieving complete clearance and achieving clearance rapidly. [J Drugs Dermatol 2007;6:144-147]

“Tolerability was similar except for erythema, which was initially significantly higher with 5-fluorouracil than imiquimod but resolved rapidly and was significantly lower than imiquimod by week 16. Five-percent 5-fluorouracil remains the gold standard field therapy for AKs,” Tanghetti and Werschler said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.